Article

Planning robust clinical trials for Shigella vaccines: A simulation-based evaluation of the impact of naturally-acquired immunity on vaccine performance

2025-12-12

Abstract excerpt

<h4>Background: </h4> Several Shigella vaccine candidates are in late stages of development, and the design of large Phase 3 trials in target populations is underway. Immunologic catch up by unvaccinated infants to vaccinated infants, which is determined by the trial site-specific force of infection, may modify the vaccine efficacy (VE) estimates observed in such trials. To set expectations and support optimal pla...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bd15537a-7a3d-5d80-85a9-7188b64df173
DOI: 10.64898/2025.12.11.25341848

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Planning robust clinical trials for Shigella vaccines: A simulation-based evaluation of the impact of naturally-acquired immunity on vaccine performanceDOI 10.64898/2025.12.11.25341848Read

Analyzing Vaccine Trials in Epidemics with Mild and Asymptomatic InfectionSemantic proximity Read

Status of vaccine research and development for ShigellaSemantic proximity Read

How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?Semantic proximity Read

Using simulated infectious disease outbreaks to guide the design of individually randomized vaccine trialsSemantic proximity Read

Comparing existing and novel methods for estimating etiology-specific diarrheal disease incidence in hybrid surveillance studiesSemantic proximity Read

Leveraging pathogen sequence and contact tracing data to enhance vaccine trials in emerging epidemicsSemantic proximity Read

The Shigella Vaccines PipelineSemantic proximity Read

Frontiers in Shigella Vaccine DevelopmentSemantic proximity Read

Towards establishing a correlate of protection against shigellosis: assessing immunological endpoints across immune responses to the Shigella sonnei 1790GAHB GMMA investigational vaccineSemantic proximity Read

Towards establishing correlates of protection against shigellosis: assessing immunological endpoints across immune responses to the Shigella sonnei Generalized Modules for Membrane Antigens (GMMA) candidate vaccine (1790GAHB).Semantic proximity Read

How Important Are Study Designs? A Simulation Assessment of Vaccine Effectiveness Estimation Bias with Time-Varying Vaccine Coverage, and Heterogeneous Testing and Baseline Attack RatesSemantic proximity Read

Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity scoreSemantic proximity Read